Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ImmunityBio (IBRX)
NASDAQ:IBRX
Holding IBRX?
Track your performance easily
IBRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.10 - $10.53
Previous Close$5.1
Volume3.42M
Average Volume (3M)5.08M
Market Cap
$3.55B
Enterprise Value$4.44B
Total Cash (Recent Filing)$130.37M
Total Debt (Recent Filing)$1.02B
Price to Earnings (P/E)―
Beta1.90
Next Earnings
May 08, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.89
Shares Outstanding696,831,296
10 Day Avg. Volume5,375,126
30 Day Avg. Volume5,083,892
Standard Deviation0.36
R-Squared0.02
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)-4.56
Price to Sales (P/S)508.46
Price to Cash Flow (P/CF)-9.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue605.70
Enterprise Value/Gross Profit7.14K
Enterprise Value/Ebitda-11.68
Forecast
1Y Price Target
$17.38Price Target Upside240.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
ImmunityBio News
PremiumCompany Announcements
ImmunityBio Inc. Reports Earnings Amid Financial Challenges
Ownership Overview
51.65% Insiders
2.73% Mutual Funds
0.92% Other Institutional Investors
40.36% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IBRX FAQ
What was ImmunityBio’s price range in the past 12 months?
ImmunityBio lowest stock price was $3.10 and its highest was $10.53 in the past 12 months.
What is ImmunityBio’s market cap?
Currently, no data Available
When is ImmunityBio’s upcoming earnings report date?
ImmunityBio’s upcoming earnings report date is May 08, 2025 which is in 165 days.
How were ImmunityBio’s earnings last quarter?
ImmunityBio released its earnings results on Nov 12, 2024. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.178 by $0.038.
Is ImmunityBio overvalued?
According to Wall Street analysts ImmunityBio’s price is currently Undervalued.
Does ImmunityBio pay dividends?
ImmunityBio does not currently pay dividends.
What is ImmunityBio’s EPS estimate?
ImmunityBio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmunityBio have?
ImmunityBio has 696,831,300 shares outstanding.
What happened to ImmunityBio’s price movement after its last earnings report?
ImmunityBio reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.178. Following the earnings report the stock price went down -9.174%.
Which hedge fund is a major shareholder of ImmunityBio?
Among the largest hedge funds holding ImmunityBio’s share is Woodline Partners LP. It holds ImmunityBio’s shares valued at 2M.
---
ImmunityBio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.38 (240.78% Upside)
$17.38 (240.78% Upside)
Blogger Sentiment
Bullish
IBRX Sentiment 90%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 12.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 14.7%
Last 30 Days ▲ 14.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.69%
Trailing 12-Months
Company Description
ImmunityBio
NantKwest, Inc. engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The firm operates through the following geographical segments: United States; Europe; and Other Non-U.S. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA.
---
IBRX Stock 12 Month Forecast
Average Price Target
$17.38
▲(240.78% Upside)
Technical Analysis
Best Analysts Covering IBRX
1 Year
1 Year Success Rate
2/5 ratings generated profit
1 Year Average Return
+36.26%
reiterated a buy rating 3 months ago
Copying Kelly Shi's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +36.26% per trade.
---